CMG-12

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCMG-12
Drug Alias NameCMG-12
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-PD-1Anti-CTLA4
TargetsProgrammed cell death protein 1Cytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesChengdu Chimagen Biosciences Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChengdu Chimagen Biosciences Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A